How MAYZENT works in SPMS with active disease.
MAYZENT is a novel therapy for SPMS with active disease1
Selective S1P1 and S1P5 receptor modulator1
-
Potent effect on S1P1 and S1P5 receptors, which are widely expressed on cells of the immune system and the CNS.
Impacts MS pathology1–4
- Inhibits the egress of lymphocytes from lymph nodes to reduce CNS inflammation.
Distribution and elimination1
- Readily crosses the blood-brain barrier.
- Short half-life of ~30 hours with a washout period of around 10 days.
Indication: MAYZENT is indicated for the treatment of adult patients with SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.5
CNS, central nervous system; MS, multiple sclerosis; S1P, sphingosine-1-phosphate; SPMS, secondary progressive multiple sclerosis.
References
- Novartis DOF_GLNS_SIPO_0127.
- Kappos L et al. Lancet. 2018;391:1263–1273, plus supplementary appendix.
- Benedict RHB et al. Impact of siponimod on cognition in patients with secondary progressive multiple sclerosis: results from the phase 3 EXPAND study. Poster presented at: AAN Meeting; 26 April 2018; Los Angeles, CA, USA.
- Arnold DL et al. Presented at: the 35th ECTRIMS Congress; 11–13 September 2019; Stockholm, Sweden.
- MAYZENT (siponimod) Summary of Product Characteristics.
SIP20-C001c May 2020.
